- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 13 - Final Insights
During the conclusion of this panel discussion, the panelists provide their final insights about managed care’s role in castration-resistant prostate cancer (CRPC).
E. David Crawford, MD, explains that as agents continue to develop for the treatment of CRPC, there is a need to better evaluate their roles. He explains that managed care needs to assess which factors are most important to patients and third-party payers.
Michael Kolodziej, MD, explains that although CRPC has entered an exciting era, there are many outstanding challenges that need to be addressed.
Jeffrey D. Dunn, PharmD, MBA, believes that managed care needs to focus on cost trends, address payment reform, invest in information technology, and improve coordination between stakeholders.
David Quinn, MD, suggests that achieving the primary goal of improving care for patients with CRPC begins with a commitment by managed care. He explains that managed care needs to determine which treatment options are the most cost-effective.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
